Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Ceredase.

Drug combinations


Alglucerase: C~2532~H~3854~N~672~O~711~S~16~ (protein moiety). 59,300 (SDS-PAGE determined). A modified form of human placental tissue β-glucocerebrosidase (β-D-glucosyl-N-acylsphingosine glucohydrolase). It is a monomeric glycoprotein of 497 aa; approximately 12% of the glycoprotein consists of N-linked carbohydrate chains of the complex and high mannose type. (1) Glucosylceramidase (human placenta isoenzyme protein moiety reduced); (2) Glucosylceramidase (human placenta isoenzyme protein moiety reduced). CAS-143003-46-7 (1992).

Pharmacologic Category

Enzymes. (ATC-Code: A16AB01).

Mechanism of action

Alglucerase is a modified form of glucocerebrosidase enzyme, prepared from human placental tissue. Glucocerebrosidase catalyzes the hydrolysis of glucocerebroside to glucose and ceramide.

Therapeutic use

Replacement therapy for Gaucher’s disease (type 1).

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to any component of the formulation.

Warnings and precautions

Derived from pooled human placental tissue that may contain agents of some viral diseases. Hypersensitivity reactions may occur (patients who develop IgG antibodies may be at a higher risk). May cause early virilization in males <10 years of age. Use with caution in androgen-sensitive malignancies.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart